“Maximum tolerated dose” vs “fixed low-dose” hydroxyurea for treatment of adults with sickle cell anemia

Authors

Titilola S. Akingbola, University College Hospital, Ibadan
Bamidele O. Tayo, Stritch School of Medicine
Chinedu A. Ezekekwu, University College Hospital, Ibadan
Omowunmi Sonubi, University College Hospital, Ibadan
Xu Zhang, University of Illinois at Chicago
Santosh L. Saraf, University of Illinois at Chicago
Robert Molokie, University of Illinois at Chicago
Lewis L. Hsu, University of Illinois at Chicago
Jin Han, University of Illinois at Chicago
Richard S. Cooper, Stritch School of Medicine
Victor R. Gordeuk, University of Illinois at Chicago

Document Type

Letter to the Editor

Publication Date

4-1-2019

Publication Source (Journal or Book title)

American Journal of Hematology

First Page

E112

Last Page

E115

Recommended Citation

Akingbola, T., Tayo, B., Ezekekwu, C., Sonubi, O., Zhang, X., Saraf, S., Molokie, R., Hsu, L., Han, J., Cooper, R., & Gordeuk, V. (2019). “Maximum tolerated dose” vs “fixed low-dose” hydroxyurea for treatment of adults with sickle cell anemia. American Journal of Hematology, 94 (4), E112-E115. https://doi.org/10.1002/ajh.25412